Zentalis Pharmaceuticals, Inc. (ZNTL)
NASDAQ: ZNTL · Real-Time Price · USD
2.480
+0.185 (8.06%)
At close: Mar 9, 2026, 4:00 PM EDT
2.490
+0.010 (0.40%)
After-hours: Mar 9, 2026, 5:56 PM EDT
Company Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States.
The company develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types.
It also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer.
It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Zentalis Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2014 |
| IPO Date | Apr 3, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 166 |
| CEO | Julie Eastland |
Contact Details
Address: 10275 Science Center Dr., Suite 200 San Diego, California 92121 United States | |
| Phone | 212 433 3791 |
| Website | zentalis.com |
Stock Details
| Ticker Symbol | ZNTL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0001725160 |
| CUSIP Number | 98943L107 |
| ISIN Number | US98943L1070 |
| Employer ID | 82-3607803 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Julie M. Eastland M.B.A. | Chief Executive Officer, President and Director |
| Vincent A. Vultaggio | SVice President of Finance and Principal Accounting Officer |
| Robert J. DiVasto P.E. | Chief Technical Officer |
| James B. Bucher J.D. | Chief Legal Officer and Corporate Secretary |
| Wendy Chang | Chief People Officer |
| Dr. Ingmar Bruns M.D., Ph.D. | Chief Medical Officer |
| Haibo Wang | Chief Business Officer |
| Rajesh Israni | Executive Vice President of Regulatory Affairs and Medical Writing |
| Henry Gu | Senior Vice President and Head of Intellectual Property |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 3, 2026 | SCHEDULE 13G | Filing |
| Jan 9, 2026 | 8-K | Current Report |
| Jan 5, 2026 | SCHEDULE 13G/A | Filing |
| Jan 2, 2026 | SCHEDULE 13D/A | Filing |
| Dec 30, 2025 | SCHEDULE 13G | Filing |
| Dec 15, 2025 | SCHEDULE 13D/A | Filing |
| Dec 15, 2025 | 8-K | Current Report |
| Nov 12, 2025 | SCHEDULE 13G | Filing |
| Nov 10, 2025 | 10-Q | Quarterly Report |
| Nov 10, 2025 | 8-K | Current Report |